Stifel Initiates Coverage of Cereno Scientific with Buy Rating

Got story updates? Submit your updates here. ›

Cereno Scientific, an innovative biotech company pioneering treatments for rare cardiovascular and pulmonary diseases, announced that global investment bank Stifel has initiated equity research coverage with a Buy rating and a price target of $2.25 per share. The coverage highlights the potential of Cereno's clinical pipeline, including its lead candidate CS1 which has shown promising results in a Phase IIa study for pulmonary arterial hypertension.

Why it matters

The initiation of coverage by Stifel is seen as an important milestone for Cereno Scientific as it aims to expand engagement with the global investment community. Independent equity research can help increase transparency and support a deeper understanding of the company's strategy, clinical progress, and value potential.

The details

Stifel's analysis, led by healthcare analyst Oscar Haffen Lamm, introduces Cereno Scientific to a broader base of international investors and analysts. The coverage highlights the potential of Cereno's lead candidate CS1, which has demonstrated encouraging efficacy signals in a Phase IIa study for pulmonary arterial hypertension (PAH) and is advancing toward a Phase IIb trial planned to start in Q2 2026. Stifel's $2.25 price target reflects its view of the growth opportunity for Cereno's differentiated approach to developing disease-modifying therapies for rare diseases with significant unmet medical need.

• Cereno Scientific announced Stifel's initiation of coverage on March 27, 2026.
• Cereno's lead candidate CS1 is advancing toward a Phase IIb trial planned to start in Q2 2026.

What they’re saying

What’s next

Cereno Scientific plans to start a Phase IIb trial for its lead candidate CS1 in Q2 2026.